Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Migraine Without Aura Clear all

Conditions: Migraine
Interventions: DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B), Placebo (treatment C); Drug · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Long Beach, California • Santa Monica, California • Watertown, Massachusetts + 3 more

Conditions: Migraine With and Without Aura, Chronic Migraine, Healthy Controls
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Interventions: Rimegepant, Zavegepant; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Episodic Migraine, Chronic Migraine
Interventions: Aspirin (acetylsalicylic acid), Placebo; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Migraine, Pain, Nausea, Vomiting, Aura
Interventions: Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo; Drug · Other
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina

Conditions: Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
Interventions: TNX-1900, Placebo Nasal Spray; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 26
States / cities: Little Rock, Arkansas • Lemon Grove, California • Oceanside, California + 23 more

Conditions: Migraine
Interventions: EVO756, Dose 1, EVO756, Dose 2, Placebo; Drug
Lead sponsor: Evommune, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Chandler, Arizona • Buena Park, California • Fresno, California + 31 more

Conditions: Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions: 40 minute session, 20 minute session, home practice e-health, home practice handout, phone call; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 17 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Cincinnati, Ohio

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Migraine With or Without Aura
Interventions: Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Migraine, With or Without Aura
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 50
States / cities: Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more

Conditions: Migraine
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 109
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more

Conditions: Episodic Migraine
Interventions: DFN-11, Placebo; Drug · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 16
States / cities: Santa Monica, California • Jacksonville, Florida • Maitland, Florida + 13 more

Conditions: Migraine Headache, With or Without Aura
Interventions: Staccato Placebo, Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Mount Vernon, New York

Conditions: Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions: milnacipran; Drug
Lead sponsor: California Medical Clinic for Headache; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Dihydroergotamine, Placebos; Drug
Lead sponsor: Satsuma Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more

Conditions: Migraine Disorders
Interventions: sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 49
States / cities: Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more

Conditions: Migraine With or Without Aura
Interventions: Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 3,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more

Conditions: Migraine With Aura, Migraine Without Aura
Interventions: Dronabinol MDI; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 29
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more

Conditions: Tinnitus
Interventions: Nortriptyline, Topiramate, Paroxetine, Verapamil; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 25 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Orange, California

Conditions: Migraine Headache, Aura
Interventions: Inhaled Placebo, Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 25
States / cities: Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 22 more

Conditions: Migraine Headache
Interventions: Placebo, LY2300559; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Phoenix, Arizona • Long Beach, California • Fairfield, Connecticut + 8 more

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Dihydroergotamine; Drug
Lead sponsor: Satsuma Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 44
States / cities: Encino, California • Long Beach, California • Los Alamitos, California + 40 more

Conditions: Migraine Headache
Interventions: DFN-15 Active, DFN-15 Placebo; Drug · Other
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Search by objective public record fields.

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

Migraine and Body Composition

A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

Aspirin Resistance in Women With Migraine

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Study of EVO756 in Adults With Migraine

Mind Body Balance for Pediatric Migraine

A Study of a Melatonin Receptor Agonist to Prevent Migraine

An Acute Migraine Factorial Study

Safety and Efficacy in Adult Subjects With Acute Migraines

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

DFN-11 Injection in Episodic Migraine With or Without Aura

Staccato Prochlorperazine in Migraine (in Clinic)

Preventive Treatment of Episodic and Chronic Migraine

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

Management of Acute Tinnitus With Migraine Medications

Staccato Prochlorperazine in Migraine (Out Patient)

A Study in Migraine Prevention

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

Efficacy, Tolerability, and Safety Study of DFN-15